Mary Denny is a Neurology physician. OpenAlex indexes 82 publications with 996 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
Suite 1014
Houston, TX 770303000
Telephone
832-325-7080Registry record last updated 23 Apr 2016.
Clinical trials
- Stroke Transitions of Care to Reduce Hospital Length of Stay
Sponsor: Georgetown University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- ABBVIE INC.Program year20241 payment
- Abbott LaboratoriesProgram year202310 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
39.6%Gabapentinoids12.7%Gabapentin56%Pregabalin44%Part D<11 patientsTricyclic Antidepressant12.3%Nortriptyline Hcl100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
32.5%Statin27.4%Atorvastatin Calcium60%Rosuvastatin Calcium40%Part D≥13 patientsCalcium channel blocker5.2%Amlodipine Besylate100%Part D<11 patientsBlood & clotting
27.8%Factor Xa inhibitor14.2%Eliquis100%Part D<11 patientsP2Y12 inhibitor13.7%Brilinta55%Clopidogrel45%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Opportunities in stroke care at safety net hospitals: A socioecological perspective
Equity Neuroscience
2025 - Addressing Disparities in Acute Stroke Management and Prognosis
Journal of the American Heart Association
2024 - A Cross-sectional Survey of Comprehension and Satisfaction of Spanish-Reading Adults Regarding RÁPIDO as a Stroke Awareness Acronym
Journal of Neuroscience Nursing
2024 - Inequities in Telemedicine Use Among Patients With Stroke and Cerebrovascular Diseases
Neurology Clinical Practice
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”